OA11189A - Quinoxalinediones. - Google Patents

Quinoxalinediones. Download PDF

Info

Publication number
OA11189A
OA11189A OA9900192A OA9900192A OA11189A OA 11189 A OA11189 A OA 11189A OA 9900192 A OA9900192 A OA 9900192A OA 9900192 A OA9900192 A OA 9900192A OA 11189 A OA11189 A OA 11189A
Authority
OA
OAPI
Prior art keywords
formula
compound
solvaté
group
acceptable sait
Prior art date
Application number
OA9900192A
Other languages
English (en)
Inventor
Robert James Crook
Elisabeth Colette Loui Gautier
Alan Stobie
David Charles Waite
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP1997/000995 external-priority patent/WO1997032873A1/en
Priority claimed from GBGB9715783.8A external-priority patent/GB9715783D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of OA11189A publication Critical patent/OA11189A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
OA9900192A 1997-02-27 1999-08-23 Quinoxalinediones. OA11189A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP1997/000995 WO1997032873A1 (en) 1996-03-09 1997-02-27 Quinoxalinediones
GBGB9715783.8A GB9715783D0 (en) 1997-02-27 1997-07-25 Quinoxalinediones

Publications (1)

Publication Number Publication Date
OA11189A true OA11189A (en) 2003-05-14

Family

ID=10816496

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900192A OA11189A (en) 1997-02-27 1999-08-23 Quinoxalinediones.

Country Status (14)

Country Link
US (1) US6333326B1 (ko)
KR (1) KR100375112B1 (ko)
AP (1) AP982A (ko)
AU (1) AU723467B2 (ko)
DZ (1) DZ2437A1 (ko)
EA (1) EA001658B1 (ko)
GT (1) GT199800045A (ko)
HK (1) HK1025317A1 (ko)
IL (1) IL131120A0 (ko)
IS (1) IS5142A (ko)
MA (1) MA26474A1 (ko)
OA (1) OA11189A (ko)
PL (1) PL335501A1 (ko)
UA (1) UA58534C2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL359340A1 (en) * 2000-05-19 2004-08-23 Triazole derivatives
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
EP2150248A4 (en) 2007-01-16 2011-06-29 Univ Johns Hopkins GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE
CN101679383B (zh) 2007-05-17 2014-10-29 株式会社半导体能源研究所 三唑衍生物，和使用三唑衍生物的发光元件、发光器件和电子器件

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158846A (en) 1990-10-29 1992-10-27 Olin Corporation Electrostatic color printing system utilizing an image transfer belt
IT1243990B (it) * 1990-10-30 1994-06-28 Minnesota Mining & Mfg Procedimento per preparare prodotti del bisfenolo fluorene
WO1992007847A1 (en) * 1990-11-06 1992-05-14 Yamanouchi Pharmaceutical Co., Ltd. Fused pyrazine derivative
GB9605027D0 (en) * 1996-03-09 1996-05-08 Pfizer Ltd Quinoxalinediones

Also Published As

Publication number Publication date
KR20000075717A (ko) 2000-12-26
AU723467B2 (en) 2000-08-24
IS5142A (is) 1999-07-30
AP982A (en) 2001-07-16
EA199900688A1 (ru) 2000-04-24
KR100375112B1 (ko) 2003-03-08
HK1025317A1 (en) 2000-11-10
PL335501A1 (en) 2000-04-25
EA001658B1 (ru) 2001-06-25
IL131120A0 (en) 2001-01-28
UA58534C2 (uk) 2003-08-15
MA26474A1 (fr) 2004-12-20
GT199800045A (es) 1999-08-20
DZ2437A1 (fr) 2003-01-11
US6333326B1 (en) 2001-12-25
AU6827998A (en) 1998-09-18

Similar Documents

Publication Publication Date Title
JP2022071072A (ja) （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用
EP1716135B1 (en) Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists
JP2002541103A (ja) ピロリジン系ケモカイン受容体活性調節剤
TW201035077A (en) Soluble guanylate cyclase activators
EP2763978B1 (en) Carbamate/ urea derivatives containing piperidin and piperazin rings as h3 receptor inhibitors
JP7130873B2 (ja) バニン阻害剤としてのヘテロ芳香族化合物
CN111433196A (zh) 新颖缓激肽b2受体拮抗剂及其用途
SK105294A3 (en) Indole derivatives, method of their preparation, intermediates of this process, pharmaceutical agents containing these derivatives and use of these derivatives
TW202023550A (zh) 作為vanin抑制劑之雜芳族化合物
TW201726688A (zh) Ｎ－［２－（２－胺基－６，６－二取代－４，４ａ，５，６－四氫哌喃［３，４－ｄ］［１，３］噻－８ａ（８Ｈ）－基）－１，３－噻唑－４－基］醯胺
JP3026945B2 (ja) ３−アザ及び３−オキサピペリドンタキキニン拮抗薬
EP0973766B1 (en) Quinoxalinediones
JP2022525697A (ja) Ｄｒｐ１－フィラミン複合体形成阻害剤
OA11189A (en) Quinoxalinediones.
NZ248776A (en) Imidazole-substituted piperidine derivatives; pharmaceutical compositions and preparatory methods
TW201726687A (zh) Ｎ－（２－（２－胺基－６－取代－４，４ａ，５，６－四氫哌喃并［３，４－ｄ］［１，３］－８ａ（８Ｈ）－基）－噻唑－４－基）醯胺類
WO2023187715A1 (en) Complement factor b inhibitors and uses thereof
TWI782523B (zh) 用作ret激酶抑制劑的化合物及其應用
TW200819448A (en) Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition
CZ9903052A3 (cs) Chinoxalindiony, způsoby a meziprodukty pro jejich výrobu, jejich použití, farmaceutické přípravky na jejich bázi a způsoby léčení
WO2023227867A1 (en) Heterobicyclic amides as inhibitors of cd38
MXPA99007937A (en) Quinoxalinediones
CA3219801A1 (en) Substituted heterobicyclic derivatives as negative allosteric modulators of mglu7 receptor
TW202417451A (zh) 抑制irak4活性的化合物及其應用
WO2022249006A1 (en) Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists